Dengue – pipeline review, h2 2012


Published on

Aarkstore Enterprise-Dengue – Pipeline Review, H2 2012

Published in: Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Dengue – pipeline review, h2 2012

  1. 1. announces, The Latest market research report is available inits vast collection:Dengue – Pipeline Review, H2 2012You can also request for sample page of above mention reports onsample@aarkstore.comSummaryGlobal Markets Direct’s, Dengue - Pipeline Review, H2 2012, provides an overviewof the indication’s therapeutic pipeline. This report provides information on thetherapeutic development for Dengue, complete with latest updates, and specialfeatures on late-stage and discontinued projects. It also reviews key playersinvolved in the therapeutic development for Dengue. Dengue - Pipeline Review, HalfYear is built using data and information sourced from Global Markets Direct’sproprietary databases, Company/University websites, SEC filings, investorpresentations and featured press releases from company/university sites andindustry-specific third party sources, put together by Global Markets Direct’s team.Note*: Certain sections in the report may be removed or altered based on theavailability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Dengue.- A review of the Dengue products under development by companies anduniversities/research institutes based on information derived from company andindustry-specific sources.
  2. 2. Reasons to buy- Identify and understand important and diverse types of therapeutics underdevelopment for Dengue.- Identify emerging players with potentially strong product portfolio and designeffective counter-strategies to gain competitive advantage.Table of contents:List of Tables 7List of Figures 8Introduction 9Global Markets Direct Report Coverage 9Dengue Overview 10Therapeutics Development 11An Overview of Pipeline Products for Dengue 11Dengue Therapeutics under Development by Companies 13Dengue Therapeutics under Investigation by Universities/Institutes 16Late Stage Products 18Comparative Analysis 18Mid Clinical Stage Products 19Comparative Analysis 19Early Clinical Stage Products 20Comparative Analysis 20Discovery and Pre-Clinical Stage Products 21Comparative Analysis 21Dengue Therapeutics – Products under Development by Companies 22Dengue Therapeutics – Products under Investigation by Universities/Institutes 23Companies Involved in Dengue Therapeutics Development 24Vical Incorporated 24GenVec, Inc. 25Merck & Co., Inc. 26Biotron Limited 27Alfacell Corporation 28AVI BioPharma Inc. 29
  3. 3. Medivir AB 30NanoViricides, Inc. 31SIGA Technologies, Inc. 32MacroGenics, Inc. 33Canopus BioPharma Incorporated 34GenPhar, Inc. 35Ikaria Inc. 36List of FiguresList of Tables are also include.For more related Reports Plz follow The link:Pipeline Review, H2 2012 Review, H22012&PubId=&pagenum=1Neutropenia – Pipeline Review, H2 2012Amyloidosis – Pipeline Review, H2 2012Human Papillomavirus Infections – Pipeline Review, H2 2012Cancer Pain – Pipeline Review, H2 2012Dengue – Pipeline Review, H2 2012
  4. 4. Gastrointestinal Tract Cancer – Pipeline Review, H2 2012 Diabetes – Pipeline Review, H2 2012 Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2012 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline Review,H2 2012 Graft Versus Host Disease (GVHD) – Pipeline Review, H2 2012 Malaria – Pipeline Review, H2 2012 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections – Pipeline Review,H2 2012 Dermatitis – Pipeline Review, H2 2012Search More Reports Related to This Category :Pharmaceuticals and Healthcare andHealthcare&PubId=&pagenum=1For More details Plz do contact :Aarkstore EnterpriseLavanyaPhone:08149852585Email: